Ambit to Profile Additional Compounds for Bristol-Myers, GSK, Pfizer

genomeweb
360dx

Ambit to Profile Additional Compounds for Bristol-Myers, GSK, Pfizer

Jan 17, 2005

NEW YORK, Jan. 17 (GenomeWeb News) - Ambit Biosciences will profile additional compounds for Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer using its kinase and screening technologies, the San Diego-based company said today.

To read the full story....

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Meridian Bioscience's Q2 Revenues Up 4 Percent, Beat Estimates
Roche Q1 Diagnostics Revenues Rise 5 Percent, Liat Sales Surge
Radboud UMC, NimaGen Partner to Develop Targeted Sequencing Kits
FDA Grants Breakthrough Device Designation to Foundation Medicine Liquid Biopsy Assay
10x Genomics Closes $50M Financing Round, $75M Credit Facility
3,000 Rice Genomes Project Sequences Reveal Asian Rice History, Diversity

The Scan

This Week in Nature

In Nature this week: ash dieback disease fungal genome, and more.

Now You Can Read Them, Now You Can't

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

The Mouths of Heavy Drinkers Are Disgusting

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

For Health or For Fun?

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

Main menu